...
首页> 外文期刊>Annals of allergy, asthma, and immunology >Low risk of contrast media-induced hypersensitivity reactions in all subtypes of systemic mastocytosis
【24h】

Low risk of contrast media-induced hypersensitivity reactions in all subtypes of systemic mastocytosis

机译:造影剂诱导的超敏反应在所有系统性肥大细胞增多症亚型中的风险较低

获取原文
获取原文并翻译 | 示例

摘要

Background: Patients with systemic mastocytosis (SM) are at increased risk of hypersensitivity reactions (HRs). Although Hymenoptera venoms are the predominant triggers, cases of contrast media-induced HR (CMIHR) have also been reported and prophylactic premedication is often performed. However, data from larger series are limited and differences between indolent and advanced SM have not yet been investigated. Objective: To determine the incidence and severity of CMIHR in all subtypes of SM. Methods: We analyzed 162 adult patients with SM (indolent systemic mastocytosis ISM, n = 65; advanced systemic mastocytosis advSM, n = 97). First, the cumulative incidence of CMIHR was retrospectively assessed in the patient's history. Second, at our institution, patients underwent 332 contrast media (CM)-enhanced imaging including 80 computed tomography (CT) scans with iodine-based contrast agent and 252 magnetic resonance imaging (MRI) with a gadolinium-based contrast agent, and tolerance was assessed. Results: Previous CMIHRs to CT (vomiting, n = 1, erythema, n = 1, cardiovascular shock, n = 1), and MRI (dyspnea, n = 1, cardiovascular shock, n = 1) had been reported by 4 out of 162 (2.5) patients (ISM, n = 3; advSM, n = 1). In contrast, during or after 332 CM-enhanced CT or MRI examinations at our institution, no CMIHRs were reported. Premedication was solely given to 3 patients before CT scans, including 1 with previous CMIHR, who tolerated the imaging well. Conclusion: We conclude that: (1) there is a substantial discrepancy between the perception and prevalence of HRs to CM in SM; (2) reactions are scarce in ISM and even rarer in advSM; and (3) in SM patients without previous history of CM hypersensitivity, prophylactic premedication before CM-enhanced CT or MRI is dispensable. (c) 2021 American College of Allergy, Asthma Immunology. Published by Elsevier Inc. All rights reserved.
机译:背景:系统性肥大细胞增多症 (SM) 患者发生超敏反应 (HR) 的风险增加。虽然膜翅目毒液是主要诱因,但也有造影剂诱导 HR (CMIHR) 病例的报道,并且经常进行预防性术前用药。然而,来自更大系列的数据有限,并且尚未研究惰性和晚期 SM 之间的差异。目的:确定CMIHR在SM所有亚型中的发生率和严重程度。 方法:分析162例成年SM患者(惰性系统性肥大细胞增多症[ISM],n=65;晚期系统性肥大细胞增多症[advSM],n=97)。首先,回顾性评估患者病史中CMIHR的累积发生率。其次,在我们机构,患者接受了 332 次造影剂 (CM) 增强成像,包括 80 次使用碘造影剂的计算机断层扫描 (CT) 扫描和 252 次使用钆造影剂的磁共振成像 (MRI),并评估了耐受性。结果:162 例患者中有 4 例 (2.5%) 报告了既往 CMIHR 的 CT(呕吐,n = 1,红斑,n = 1,心血管休克,n = 1)和 MRI(呼吸困难,n = 1,心血管休克,n = 1)(ISM,n = 3;advSM,n = 1)。相比之下,在我们机构进行 332 次 CM 增强 CT 或 MRI 检查期间或之后,没有报告 CMIHR。在 CT 扫描前仅对 3 例患者进行了术前用药,其中 1 例既往接受过 CMIHR 的患者,其影像学耐受性良好。结论:我们得出的结论是:(1)SM患者HR对CM的感知和患病率存在显著差异;(2)反应在ISM中很少,在advSM中更是罕见;(3)对于既往无 CM 超敏反应史的 SM 患者,在 CM 增强 CT 或 MRI 之前预防性用药是可有可无的。(c) 2021 年美国过敏、哮喘和免疫学会。由以下开发商制作:Elsevier Inc.保留所有权利。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号